Efficacy and Safety of Botulinum Toxin Type A Haemagglutinin Complex Next Generation (BTX-A-HAC NG) in Glabellar Lines

NCT ID: NCT02493946

Last Updated: 2022-09-28

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 600 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-04-30
• Study Completion Date: 2016-12-31

Brief Summary

The purpose of the protocol is to demonstrate the safety and the efficacy of a single injection of a new formulation of Clostridium Botulinum toxin type A haemagglutinin complex (BTX A HAC NG) to improve the appearance of moderate to severe glabellar lines (the lines between the eyebrows) and to assess the long term efficacy and safety of BTX-A-HAC NG after repeated injections.

Detailed Description

This is a multicentre study conducted in two periods. Subjects will first be enrolled to enter the double blind (DB) period Cycle 1. Subjects who are eligible for retreatment will then be offered to enter open label (OL) Cycles 2 to 5 as DB roll-over subjects. Once recruitment of the DB period is complete, the study will enrol additional BTX-naïve subjects (hereafter referred to as OL de novo subjects) into the OL period Cycle 1. All OL de novo subjects who are eligible for retreatment will also be offered to enter OL Cycles 2 to 5. A total of 580 subjects (180 subjects randomised in the DB period and an additional 400 de novo subjects in the OL period) are planned to complete the study.

Conditions

Glabellar Lines

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

BTX-A-HAC NG

Clostridium Botulinum Toxin Type A (BTX A HAC NG), total treatment volume 0.25mL will be divided into 5 injections (0.05mL per injections) injected in 5 pre-defined sites across the glabellar region. A total of 50 Units of BTX-A-HAC NG will be injected/ cycle.

Group Type: EXPERIMENTAL

Botulinum toxin type A

Intervention Type: BIOLOGICAL

Placebo

The total placebo volume 0.25mL will be divided into 5 injections (0.05mL per injections) injected in 5 pre-defined sites across the glabellar region. Administered in Cycle 1 of the double blind phase only.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Interventions

Botulinum toxin type A

Intervention Type: BIOLOGICAL

Placebo

Intervention Type: DRUG

Other Intervention Names

BTX-A-HAC NG

Eligibility Criteria

Inclusion Criteria

• Provision of written informed consent prior to any study related procedures.
• Male or female subjects between 18 and 65 years of age.
• Have moderate or severe (Grade 2 or 3) vertical glabellar lines at maximum frown at Baseline (Day 1), as assessed by the ILA using a validated 4- point photographic scale.
• Have moderate or severe (Grade 2 or 3) vertical glabellar lines at maximum frown at Baseline (Day 1), as assessed by the SSA using a validated 4-point categorical scale.
• Are dissatisfied or very dissatisfied (Grade 2 or 3) with their glabellar lines at Baseline (Day 1), as assessed by the subject's level of satisfaction.
• Have a negative pregnancy test (for females of childbearing potential only). No childbearing potential is defined as post-menopausal for at least 1 year, surgical sterilisation at least 3 months before entering the study, or hysterectomy.
• Have both the time and the ability to complete the study and comply with study instructions.

Exclusion Criteria

• Previous treatment with any serotype of BTX.
• Any prior treatment with permanent fillers in the upper face including the glabellar lines area.
• Any prior treatment with any dermal fillers in the upper face including the glabellar lines area within the past 3 years and/or skin abrasions/resurfacing (whatever the interventional technic used) within the past 5 years, or photo rejuvenation or skin/vascular laser intervention within the past 12 months.
• Any planned facial cosmetic surgery during the study.
• A history of eyelid blepharoplasty or brow lifts within the past 5 years.
• An inability to substantially reduce glabellar lines by physically spreading them apart or lack of capacity to frown.
• An active infection or other skin problems in the upper face including the glabellar lines area (e.g. acute acne lesions or ulcers).
• Use of concomitant therapy, which in the investigator's opinion, would interfere with the evaluation of the safety or efficacy of the investigational medicinal product (IMP), including medications affecting bleeding disorders (antiplatelet agents and/or anticoagulants given for treatment or prevention of cardio/cerebro vascular diseases).
• Pregnant women, nursing mothers, or women who are planning a pregnancy during the study, or believe they may be pregnant at the start of the study. Throughout the course of the study, women of childbearing potential must use a reliable form of contraception (e.g. oral contraceptives for more than 12 consecutive weeks, or spermicide and condoms).
• Treatment with an experimental drug or use of any experimental device within 30 days prior to the start of the study and during the conduct of the study.
• Known allergy or hypersensitivity to any component of BTX-A-HAC NG.
• Clinically diagnosed significant anxiety disorder, or any other significant psychiatric disorder (e.g. depression) that might interfere with the subject's participation in the study.
• Use of medications that affect neuromuscular transmission, such as curare-like non depolarising agents, lincosamides, polymyxins, anticholinesterases and aminoglycoside antibiotics, within the past 30 days.
• A history of facial nerve palsy.
• Marked facial asymmetry, ptosis, excessive dermatochalasis, deep dermal scarring, or thick sebaceous skin.
• The presence of any other condition (e.g. neuromuscular disorder or other disorder that could interfere with neuromuscular function), laboratory finding or circumstance that, in the judgement of the investigator, might increase the risk to the subject or decrease the chance of obtaining satisfactory data to achieve the objectives of the study.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Ipsen

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Ipsen Study Director

Role: STUDY_DIRECTOR

Ipsen

Locations

Centre Médical Saint-Jean

Arras, , France

CHRU Hôpital

Besançon, , France

Cabinet Médical

Cannes, , France

MEDITI/ Clinique Science et Beauté, Villa Sylvana

Juan-les-Pins, , France

Palais de Flore

Lyon, , France

Clinique Iéna

Paris, , France

Dermatologisches Studienzentrum

Berlin, , Germany

Privatpraxis für Dermatologie und ästhetische Medizin

Berlin, , Germany

Klinik

Darmstadt, , Germany

Rosenpark Research

Darmstadt, , Germany

Medical Skin Center

Düsseldorf, , Germany

Klinik für Dermatologie

Frankfurt, , Germany

Abteilung Biochemie und Molekularbiologie Fachrichtung Kosmetikwissenschaft

Kassel, , Germany

Rote Kreuz Krankenhaus

Kassel, , Germany

Klinik

Ludwigshafen, , Germany

Hautarztpraxis Mahlow

Mahlow, , Germany

Universitäts-Hautklinik der Gutenberg Universität Mainz

Mainz, , Germany

Privatpraxis für Dermatologie und Ästhetik

München, , Germany

Praxisklinik

Münster, , Germany

Klinische Forschung Osnabrück

Osnabrück, , Germany

Hautzentrum am Starnberger See

Starnberg, , Germany

Praxis für Dermatologie und Venerologie

Wuppertal, , Germany

London Bridge Plastic Surgery

London, , United Kingdom

PHI clinic

London, , United Kingdom

Countries

France; Germany; United Kingdom

References

Hilton S, Kestemont P, Sattler G, Volteau M, Thompson C, Andriopoulos B, Prygova I, Berg AK, Ascher B. Liquid AbobotulinumtoxinA: Pooled Data From Two Double-Blind, Randomized, Placebo-Controlled Phase III Studies of Glabellar Line Treatment. Dermatol Surg. 2022 Nov 1;48(11):1198-1202. doi: 10.1097/DSS.0000000000003594. Epub 2022 Oct 7.

Reference Type: DERIVED

PMID: 36206385 (View on PubMed)

Other Identifiers

2014-003841-86

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

Y-52-52120-214

Identifier Type: -

Identifier Source: org_study_id